Hematology

Murat Osman Arcasoy, MD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3912, Durham, NC 27710
Phone (919) 684-5350
Email address arcas001@mc.duke.edu

Dr. Arcasoy's research interests include 1)The role of cytokines and cytokine receptors in hematopoietic commitment and lineage-specific differentiation 2) Mechanisms of tissue-specific expression of erythropoietin receptor (EPOR) gene and its role in lineage commitment and lineage-specific differentiation 3) Studies of the molecular basis of familial and congenital myeloproliferative disorders.4). Isolation of novel hematopoietic cytokine-responsive genes and study of their function and regulation 5). Characterization of novel non-hematopoietic functions of EPOR signaling

Dr. Arcasoy's laboratory has been studying the expression, regulation and function of the EPOR gene focusing on the function of naturally occuring mutations of the EPOR gene that result in primary familial and congenital polycythemia as well as the non-hematopoietic expression and functions of EPOR in vascular endothelium, macrophages, cardiac myocytes and cancer cells. We have also been studying global gene expression in erythroid cells from patients with polycythemia vera to better characterize the molecular signature of the disorder and develop new diagnostic tools.

Education and Training

  • Fellow in Medical Oncology, Medicine, Yale University, 1997 - 1998
  • Hematology Fellow, Medicine, Yale University, 1992 - 1993
  • Chief Medical Resident, Medicine, State University of New York at Brooklyn, 1991 - 1992
  • Medical Resident, Medicine, State University of New York at Brooklyn, 1988 - 1991
  • M.D., Aegean University School of Medicine (Turkey), 1987

Grants

Publications

Diep, Robert T., Kristin Corey, and Murat O. Arcasoy. “A novel nucleotide substitution in the 5' untranslated region of ANKRD26 gene is associated with inherited thrombocytopenia: a report of two new families..” Ann Hematol 98, no. 7 (July 2019): 1789–91. https://doi.org/10.1007/s00277-019-03632-y.

PMID
30747248
Full Text

Verstovsek, Srdan, Ruben A. Mesa, Jason Gotlib, Vikas Gupta, John F. DiPersio, John V. Catalano, Michael W. N. Deininger, et al. “Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial..” J Hematol Oncol 10, no. 1 (February 22, 2017). https://doi.org/10.1186/s13045-017-0417-z.

PMID
28228106
Full Text

Abril, Maria K., Adam S. Barnett, Kara Wegermann, Eric Fountain, Andrew Strand, Benjamin M. Heyman, Britton A. Blough, et al. “Diagnosis of Capnocytophaga canimorsus Sepsis by Whole-Genome Next-Generation Sequencing..” Open Forum Infect Dis 3, no. 3 (September 2016). https://doi.org/10.1093/ofid/ofw144.

PMID
27704003
Full Text

Shanavas, Mohamed, Uday Popat, Laura C. Michaelis, Veena Fauble, Donal McLornan, Rebecca Klisovic, John Mascarenhas, et al. “Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors..” Biol Blood Marrow Transplant 22, no. 3 (March 2016): 432–40. https://doi.org/10.1016/j.bbmt.2015.10.005.

PMID
26493563
Full Text

Verstovsek, Srdan, Ruben A. Mesa, Jason Gotlib, Richard S. Levy, Vikas Gupta, John F. DiPersio, John V. Catalano, et al. “Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I..” Haematologica 100, no. 4 (April 2015): 479–88. https://doi.org/10.3324/haematol.2014.115840.

PMID
25616577
Full Text

Stein, Brady L., Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, et al. “Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms..” J Natl Compr Canc Netw 13, no. 4 (April 2015): 424–34.

PMID
25870379
Scholars@Duke

Silhan, Leann L., Pali D. Shah, Daniel C. Chambers, Laurie D. Snyder, Gerdt C. Riise, Christa L. Wagner, Eva Hellström-Lindberg, et al. “Lung transplantation in telomerase mutation carriers with pulmonary fibrosis..” Eur Respir J 44, no. 1 (July 2014): 178–87. https://doi.org/10.1183/09031936.00060014.

PMID
24833766
Full Text

Mesa, Ruben A., Jean-Jacques Kiladjian, Srdan Verstovsek, Haifa Kathrin Al-Ali, Jason Gotlib, Heinz Gisslinger, Richard Levy, et al. “Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies..” Haematologica 99, no. 2 (February 2014): 292–98. https://doi.org/10.3324/haematol.2013.087650.

PMID
23911705
Full Text

Pages